Hyperthermia-induced apoptosis: The role of magnetic nanoparticles in targeted delivery for breast cancer treatment

Magnetochemistry is opening new frontiers in the targeted treatment of breast cancer (BC), offering a precise and innovative way to deliver therapies exactly where they're needed. Beyond drug delivery, magnetic nanoparticles (MNPs) can generate localized heat under alternating magnetic fields, initiating controlled hyperthermia that induces apoptotic cell death in tumor tissues. MNPs, particularly iron-oxide-based magnetite (Fe₃O₄) and maghemite (γ-Fe₂O₃), can be magnetically guided toward tumor sites and subsequently activated under alternating magnetic field (AMFs) (typically 100–500 kHz and 10–40 kA m −1 ) to generate therapeutic heat through Néel and Brownian relaxation losses. At the tumor, drugs can be released in a controlled manner in response to environmental cues such as pH changes, enzymes, or magnetic stimuli. By harnessing this dual role of MNPs, as targeted carriers and thermal effectors, researchers achieve spatially selective, minimally invasive treatment. Mechanistically, magnetically induced hyperthermia elevates local temperature to 42–46 °C, which triggers reactive oxygen species (ROS) generation, mitochondrial membrane depolarization, and caspase-3/9 activation—hallmarks of apoptosis in BC cells. This integrated approach not only concentrates drugs at the tumor but also sensitizes cancer cells to chemo- and radiotherapy, while minimizing systemic toxicity. Static or dynamic magnetic fields can be used to steer these particles, while their surfaces can be engineered through chemical bonding, physical encapsulation, or adsorption techniques. Moreover, combining magnetic targeting with antibody-based recognition improves specificity and therapeutic impact. While the promise of magnetochemistry in BC treatment is clear, ongoing research is essential to optimize these technologies and bring them fully into clinical practice.